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Diverse human extracellular RNAs are widely
detected in human plasma
Jane E. Freedman1, Mark Gerstein2, Eric Mick3, Joel Rozowsky2, Daniel Levy4,5, Robert Kitchen2, Saumya Das6,
Ravi Shah6, Kirsty Danielson6, Lea Beaulieu1, Fabio C.P. Navarro2, Yaoyu Wang7, Timur R. Galeev2, Alex Holman7,
Raymond Y. Kwong8, Venkatesh Murthy9, Selim E. Tanriverdi1, Milka Koupenova1, Ekaterina Mikhalev1
& Kahraman Tanriverdi1
There is growing appreciation for the importance of non-protein-coding genes in
development and disease. Although much is known about microRNAs, limitations in
bioinformatic analyses of RNA sequencing have precluded broad assessment of other forms
of small-RNAs in humans. By analysing sequencing data from plasma-derived RNA from
40 individuals, here we identiﬁed over a thousand human extracellular RNAs including
microRNAs, piwi-interacting RNA (piRNA), and small nucleolar RNAs. Using a targeted
quantitative PCR with reverse transcription approach in an additional 2,763 individuals,
we characterized almost 500 of the most abundant extracellular transcripts including
microRNAs, piRNAs and small nucleolar RNAs. The presence in plasma of many
non-microRNA small-RNAs was conﬁrmed in an independent cohort. We present
comprehensive data to demonstrate the broad and consistent detection of diverse classes of
circulating non-cellular small-RNAs from a large population.
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T
he discovery of small-RNAs, including microRNAs
(miRNAs) has dramatically altered our understanding of
the regulation of gene expression1. Extracellular miRNAs
are present in a variety of bodily ﬂuids including plasma, urine
and saliva, and these molecules are notably stable and resist
degradation despite the presence of RNase2,3. The discovery of
stable RNA outside of cells has transformed our understanding of
the role RNA may play in cell-to-cell communication and other
complex processes. In addition, expression of cellular and
extracellular miRNAs has also been associated with a wide
variety of diseases4–6. Although miRNAs are observed in the
extracellular space, little is known about the extracellular presence
of other common varieties of small human RNAs such as
piwi-interacting RNA (piRNAs) and small nucleolar RNAs
(snoRNAs), known to be key components of molecular
interactions and gene regulation in eukaryotes. piRNAs are a
distinct class of 26–31 nucleotide-long RNAs produced by a
Dicer-independent mechanism that may have function beyond
transposon silencing and snoRNAs primarily guide chemical
modiﬁcations of other RNAs, however, their expression in human
populations is unknown.
Based on limited RNA sequencing (RNAseq) data, it has been
recently suggested that human extracellular spaces may contain a
far broader array of RNAs7,8, but their rapid simultaneous
identiﬁcation has been hampered by bioinformatic limitations.
After identiﬁcation of unbiased human small-RNAs using newer
RNAseq bioinformatics pipelines, we performed a secondary
study in Framingham Heart Study (FHS) participants revealing
the range of detectable extracellular RNAs in a large human
population. These ﬁndings were conﬁrmed using an independent
cohort from the Extracellular RNA Communication Consortium.
Previous unbiased studies of exRNAs have studied very small
numbers or pooled samples for the purpose of identifying a class
of small-RNAs9. Larger human studies have shown the
distribution of exRNAs, with a focus exclusively on miRNAs.
Most previous studies, however, have been limited by measuring
only targeted miRNAs in higher numbers of individuals or more
broad measurements in very small numbers of individuals. Our
study presents the largest description of plasma-based miRNAs
and the ﬁrst description of the broad variety of extracellular
(non-miRNA) small-RNAs in a large population.
Here, we analysed sequencing data from plasma-derived RNA
from 40 individuals and identiﬁed over a thousand human
extracellular RNAs including microRNAs, piRNA, and snoRNAs.
Using a targeted quantitative PCR with reverse transcription
(RT-qPCR) approach in an additional 2,763 individuals, we
characterized almost 500 of the most abundant extracellular
transcripts. The presence in plasma of many non-microRNA,
small-RNAs was conﬁrmed in an independent cohort. These
ﬁndings show that diverse classes of circulating non-cellular
small-RNAs, beyond miRNAs, are consistently present in plasma
from multiple human populations.
Results
Gene expression in human plasma by RNAseq. To determine
the broadest number of exRNAs in human plasma, we performed
RNAseq on 40 stored plasma samples from FHS participants
(Offspring Cohort Exam 8, demographics in Supplementary
Table 1). The FHS is a community-based, prospective study with
participants undergoing an examination everyB4–8 years. Study
participants have been densely phenotyped over multiple prior
examinations. RNA was isolated from the 40 plasma samples and
RNAseq performed to determine the presence and abundance of
human small-RNAs including miRNAs and other small exRNAs.
On the basis of comparison of RNA plasma isolation kits, the
Exiqon Bioﬂuid kit was chosen for sample isolation before
RNAseq and RT-qPCR analysis (Supplementary Fig. 1). The 40
study participants had a mean age of 68±8 years of age, with an
average body mass index (BMI) of 28.2±4.3mg kg 2., 50% of
participants were female, and 50% had a prevalent cardiovascular
disease (CVD). Sequencing was performed using an ion proton
platform (see overview in Supplementary Fig. 1B). Sequencing
data were processed in the Genboree-sequencing pipeline (Fig. 1)
and comparative analyses were performed.
Analyses of RNAseq data from 40 human plasma samples
identiﬁed a total of 1,192 small human RNAs above 13 reads per
million (RPM; most abundantly expressed RNAs are listed
in Supplementary Table 1; a summary list is provided in
Supplementary Table 2A,B). As expected, miRNAs were widely
and abundantly expressed. While there were many miRNAs
identiﬁed, miR-223-3p and miR-451a were the most abundant in
plasma and accounted for 47% of all plasma-sequencing readings.
These speciﬁc miRNAs have been found to be most abundant in
previous studies10,11. While the dominance of these miRNAs
could have resulted in false negative ﬁndings for some low-
abundant targets, an extraordinary range of non-miRNA small-
RNAs was identiﬁed. In addition, patterns of relative expression
do not suggest that red blood cell lysis was the cause of the
increased expression. For miR-23a-miR-451, increased delta
quantiﬁcation cyle (Cq) values o5 would suggest little or no
haemolysis and47 would be indicative of signiﬁcant haemolysis.
This assumption is based on a previous report showing that
miR-23a is relatively stable in plasma and not affected by
haemolysis12.
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Figure 1 | Sequencing data analysis using the Genboree-sequencing
pipeline. Small-RNAseq reads were processed and quantiﬁed using the
exceRpt tool available on the Genboree Workbench. ExceRpt incorporates
several modiﬁcations to existing analysis methods used to assess cytosolic
miRNAs that speciﬁcally address experimental issues pertinent to exRNA
proﬁling, such as variable contamination of ribosomal RNAs, and the
presence of endogenous non-miRNA small-RNAs. Brieﬂy, the software
processes each sample independently through a casade of read-alignment
steps designed to remove likely contaminants and endogenous sequences
before aligning to exogenous miRNAs.
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For our samples, the delta Cq value of miR-23a and miR-451
were o5.0 in 2,179 out of 2,763 samples. Four-hundred thirty-
nine samples had values between 5.0 and 6.99, 9 samples did not
express miR451, 24 samples did not expressed miR-23a and 88
samples did not expressed either miRNA. Only 24 samples had a
value between 7.0 and 8.42 representing less than 1% of all
samples. Although not previously known to be widely present in
the circulation, we identiﬁed 144 small-RNAs that mapped to
piRNAs. piRNAs differ from miRNAs in size (26–31 nt rather
than 21–24 nt) and are known to form RNA–protein complexes
by interacting with piwi proteins that regulate either epigenetic or
post-transcriptional gene silencing13. We also found 74 snoRNAs
and although limited information is available in regard to their
expression in human tissues, they have been previously reported
in studies using RNAseq14.
Validation of piRNAs and snoRNAs in an independent cohort.
To provide external validation of identiﬁed piRNAs and
snoRNAs, we utilized a cohort that had undergone RNAseq of
plasma samples using independent RNA isolation, RNAseq
(Illumina), and analyses (see Supplementary Methods for details).
This cohort, based at the Beth Israel Deaconess Medical Center,
consisted of normal individuals (n¼ 3; 1 female; mean age
25.7±9 years) and post-myocardial infarction (MI) patients who
had plasma collected within 4 weeks after presentation (n¼ 40,
20% female, mean BMI 28.9±5.2 kgm 2). Patients studied
after MI were derived from a completed, multi-center study of
post-MI cardiac structural changes (PROSPECT-CMR study;
ClinicalTrials.gov identiﬁer: NCT00729430). Patients in this
study were enrolled 14–28 days after an acute MI, with
subsequent randomization to ﬁsh-oil therapy and follow-up at
6 months after randomization. A subset of plasma samples from
the baseline (before randomization) study visit was used for RNA
sequencing.
Using the same detection threshold as in our discovery phase
(average reads per million (RPM)Z1K combined), the replication
sample detected 111 piRNAs and 164 snoRNAs. Of note, 15% (22
of 144) piRNAs and 76% (56 out of 74) snoRNAs detected at
Z1K RPM in the FHS cohort were also detected in the
replication sample. Overlapping exRNAs were similarly abundant
in each cohort (Fig. 2) with statistically signiﬁcant correlation
between the RPM values for snoRNAs (Spearmans r¼ 0.32,
P¼ 0.02) and—to a greater extent—piRNAs (Spearman’s
r¼ 0.53, P¼ 0.01). Together, these data suggest the validity of
the presence of multiple sequences consistent with piRNA and
snoRNA species in human plasma.
exRNAs in 2,763 individuals. From the RNAseq data,
we developed a list of observed exRNAs (n¼ 485) that we
targeted using high-throughput RT-qPCR (Fluidigm BioMark
system, Methods and Supplementary Fig. 1C)15,16 in 2,763
additional participants from the FHS. To ensure reproducibility,
performance testing was conducted. cDNA replicate and
preampliﬁcation replicates had associations typically above 0.9.
This large unselected sample of FHS study participants had a
mean age of 67±9 years of age, was 54% (n¼ 1,499) female, had
an average BMI of 28.3±5.4mg kg 2, had a 23% prevalence of
CVD. After removing poorly performing assays we measured
the expression of 331 human miRNAs, 97 human piRNAs,
and 43 human snoRNAs. Because piRNAs have a 30 modiﬁcation
(20-O-methylation), we utilized a modiﬁed approach to be able to
analyse them by RT-qPCR.
The abundance and distribution of each type of small-RNA in
the FHS cohort is illustrated in Fig. 3. While there was clearly a
greater number of miRNAs expressed in plasma, we found that
50% of the FHS participants had at least 11 snoRNAs and 20
piRNAs detectable in plasma (Fig. 3). These results demonstrate
considerable variability in terms of number of exRNAs detected
in plasma in each participant as well as the overall per cent
detected (Fig. 3). Out of the 331 human miRNAs that were
measured by RT-qPCR (Fig. 4), expression ranged from a Cq
value of 12 (abundant) to 21 (lower abundance) with most Cq
values in the 18–20 range. More abundant miRNAs such as
hsa-miR-486-5p (Cq 14.8) and has-miR-451a (Cq 12) were
expressed in almost all participants. However, many lower
abundance human miRNAs had broad expression as well. In
addition to a wealth of data related to miRNA expression, we
found other human exRNAs that were present broadly within the
study sample. This is consistent with sequence analysis from a
single human plasma sample that revealed a diverse collection of
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Figure 2 | Overlapping expression of piRNAs and snoRNAs between
post-MI and FHS Cohorts. Using the same detection threshold as in our
discovery phase (average RPMZ1 K combined), the replication sample
detected 111 piRNAs and 164 snoRNAs with statistically signiﬁcant
correlation between the RPM values for snoRNAs (Spearmans r¼0.32,
P¼0.02) and piRNAs (Spearman’s r¼0.53, P¼0.01) between the FHS
and BIDMC cohorts.
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Figure 3 | Distribution of plasma exRNA expression in 2,763
Framingham Heart Study participants. From the RNAseq data we
developed a list of observed exRNAs to target using high-throughput
RT-qPCR (Fluidigm BioMark system). The expression of 331 human
miRNAs, 97 human piRNAs, and 43 human snoRNAs were measured
(Cqo23). Because piRNAs have a 30 modiﬁcation (20-O-methylation),
we utilized a modiﬁed RT-qPCR approach. The abundance and distribution
of each type of small-RNA in the FHS cohort is illustrated in Figure 3 and
shows that 50% of the FHS cohort expressed at least 11 snoRNAs and
20 piRNAs in plasma. These results demonstrate considerable variability in
terms of number of exRNAs detected in plasma in each participant as well
as the overall percent detected.
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Figure 4 | Measurement of plasma miRNAs and piRNAs by RT-qPCR in 2,763 FHS participants. The prevalence and quantity of expression for each
miRNA (a) and piRNA (b) are measured. RNAs are sorted from least to most expressed with the N and per cent expressed (that is, Cqo23). The
quantiﬁcation cycle (Cq) axis is sorted in reverse order so that expression increases from bottom to top (a) or from left to right (b) along the axis. The
mean (±s.d.) Cq values are depicted with the horizontal capped lines and small squares (a,b) or dots (b) for each RNA. Light horizontal grey gridlines
stratify RNAs by per cent of expression ato10% and490%. Red squares or dots are used for statistically signiﬁcant associations for age (Po0.05 after
adjusting for multiplicity using the FDR) and navy squares are used for RNAs not meeting statistical signiﬁcance. All supporting values included age and sex
of participants are included in Supplementary Tables 1–3 and Supplementary Data 1–3.
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exosomal RNA species among which miRNAs were the most
abundant, making up over 42% of all raw reads14.
Examination of other human exRNAs revealed highly variable
abundance of piRNAs and snoRNAs (Fig. 4b and 5a). Out of the
97 human piRNAs, abundance ranged from Cq values of 13 to 21,
although several of the most abundant piRNAs were present in
only a few individuals. Nine piRNAs were present in over 2,000
participants. Compared with the human miRNA data, this is the
ﬁrst study to show piRNAs that were ubiquitously present in
plasma as well as others that were present in subsets of the study
population. For the 43 measured snoRNAs (Fig. 5a), presence was
generally lower as compared with the piRNAs (Cq values of
18–20). Numbers of participants with detectable speciﬁc
snoRNAs ranged from 56 to 2,625. While several piRNAs were
present in fewer than 50 individuals, this was not the case for
snoRNAs.
Conﬁrmation of piRNAs. We identiﬁed sequences mapping to
piRNAs based on unbiased RNAseq, and conﬁrmed this ﬁnding
in a second independent cohort, and further conﬁrmed it by
extensive RT-qPCR. In addition, we performed two distinct
reverse transcriptase experiments to show that piRNA RT-qPCR
analyses are speciﬁc to piRNA 30modiﬁcations. Analyses of
cDNAs made for miRNAs and snoRNAs were compared with
piRNA assays by RT-qPCR and showed that our cDNA reactions
for piRNAs were speciﬁc to the piRNA 30 methylation
modiﬁcation. In addition, plasma RNA samples were treated with
sodium periodate or non-treated (nuclease-free water) followed
by RNA isolation. Sodium periodate oxidizes the RNA but plant
miRNAs and piRNAs are protected from oxidization due to their
30 methylation. We performed RT-qPCR analyses using piRNA
and miRNA assays. The piRNA assays performed equally well in
both sodium periodate treated and non-treated RNA samples; but
miRNA assays only showed expression for non-treated RNA
samples. These ﬁndings are consistent with select RNA targets
(that is, piRNAs) containing 20-O methylation modiﬁcations on
the 30-end protecting from oxidization.
Association of exRNAs with phenotype. Participants in the FHS
Offspring Cohort (at Exam 8) were primarily older with a mean
age of 67 and were 54% female (Supplementary Table 1).
We compared the expression of each exRNA in older versus
younger subjects stratiﬁed by the sample median of 66.5 years
and in males versus females. There were few exRNAs associated
with sex, but several miRNAs, piRNAs and snoRNAs were
signiﬁcantly less expressed in older subjects (Fig. 5b; full results
available in Supplementary Data 2). The average 10-year risk
for CVD using the FHS prediction model among CVD-free
individuals 30–74 years of age (N¼ 1,822) was 14±10% (range
0.9–72%). We did not ﬁnd any exRNA associated with FHS risk
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Figure 5 | Measurement of plasma snoRNAs and association with age and sex by RT-qPCR in 2,763 FHS participants. (a) The prevalence and quantity
of expression for each snoRNA are measured. RNAs are sorted from least to most expressed with the N and per cent expressed (that is, Cqo23). The
quantiﬁcation cycle (Cq) axis is sorted in reverse order so that expression increases from left to right along the axis. The mean (±s.d.) Cq values are
depicted with the horizontal capped lines and small squares for each RNA. Light horizontal grey gridlines stratify RNAs by per cent of expression ato10%
and490%. (b) Range of fold-change values associated with age (median split at 66.5 years), sex and cardiovascular risk using the Framingham Risk Score.
Red squares or boxes are used for statistically signiﬁcant associations (Po0.05 after adjusting for multiplicity using the FDR) and navy squares and/or
boxes are used for RNAs not meeting statistical signiﬁcance. There were no statistically signiﬁcant associations with sex for any of the RNAs assessed. In
contrast, 39% (n¼ 133) of miRNAs, 13% (n¼ 13) of piRNAs and 21% (n¼9) of snoRNAs were associated with age. As shown in Figure 4b and 5a, all
piRNAs and snoRNAs and all but three of the miRNAs showed increased expression in subjectso66.5 years of age. All supporting values included age and
sex of participants are included in Supplementary Tables 1–3 and Supplementary Data 1–3.
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score calculated from an individual’s age, sex, diabetes status,
smoking status, treated or untreated systolic blood pressure and
lipid levels (Fig. 5b).
Factor analysis of exRNAs in 2,763 individuals. We conducted
an exploratory principal factor analyses of the miRNAs, piRNAs
and snoRNAs in an effort to identify correlated clusters
of exRNAs the FHS cohort (full results are available in
Supplementary Table 4). For each exRNA type, inspection of the
screenplot of eigenvalues suggested that a four-factor solution
best represented the factor structure. Descriptive statistics
characterizing factor membership are presented in Table 1. Out of
the 331 miRNAs, 100 did not load on at least one of the ﬁrst four
factors. The ﬁrst miRNA factor was comprised of 108 common
and uncommon miRNAs (detection rates ranging from 11.9 to
93.5%). The second factor was comprised of 67 uncommonly
detected (o8.4% of individuals) miRNAs, while the third
was comprised of 40 very commonly detected (484.2% of indi-
viduals) miRNAs. The factors identiﬁed among the piRNAs
and snoRNAs were similarly deﬁned by the detection rate
(see Table 1).
In an attempt to further characterize these factors we
identiﬁed the potential targets of the miRNAs loading on each
factor using the miRDB Version 5.0 target predictions17 available
at (http://mirdb.org/miRDB/download.html). After limiting
targets to those target prediction scores of at least 80 we found
that the Factor-1 miRNAs potentially targeted 23,240 genes. We
also found, that these predictions demonstrate some overlap
between the factor sets (Fig. 6a). Lastly, we performed KEGG
pathway18 enrichment analysis of genes targeted by miRNAs in
factors 1–4 relative to all target genes in miRDB (Fig. 6b). We
found that several pathways showed signiﬁcant enrichment and
overlap such as MAP kinase signalling pathways and those
associated with cancer.
exRNA expression in extracellular and cellular blood sources.
To determine the relative cellular/extracellular distribution of the
miRNAs, piRNAs and snoRNAs measured in this large
population, we performed additional experiments measuring
isolated cells, plasma and exosome exRNA expression. Because of
the large number of samples (six donors, eight sample types), we
performed full exRNA analyses by RT-qPCR using the same
methodologies as described for the human samples. Each
blood component—plasma, exosomes, platelets, peripheral blood
mononuclear cells (PBMC)s, RBCs, T Cells, B Cells, and
neutrophils—was isolated as described in the Methods from six
healthy donors and ﬂow cytometry was performed to verify the
cell type isolated and to identify any potential contaminants or
expression of potential cells of origin. For plasma, the sample had
minor contamination (from other cell types, Supplementary
Fig. 2) but this was, as expected, variable based on the speciﬁc
sample and could be cellular fragments that were not cleared
during centrifugation vs markers of the cell of origin. Thus, it
cannot be determined whether these markers are representative of
the cells of origin for the exosome vs contamination during
preparation. This is a limitation of exRNA studies. For exosomes,
the sample was positive for CD9 (an exosome marker; Po0.001
by least-squares regression models) and negative for platelets. For
platelets, the sample was positive for CD41 (a platelet marker;
Po0.001) and o5% positive for all other cell markers, except
RBCs (11.1%±0.95) and neutrophils (11.8%±2.22). Abundance
of each class of exRNAs relative to plasma is shown in Table 2.
For piRNAs and snoRNAs, while many were found to be
non-signiﬁcantly different, some cellular forms had increased
abundance as compared with plasma. Interestingly, for exosomes,
most were not signiﬁcantly different or decreased (‘upregulated in
plasma’) as compared with plasma. For miRNAs, few were
increased in plasma relative to cells/exosomes, reﬂecting the
separation methods used.
Discussion
This study is the ﬁrst systematic description of extracellular non-
miRNA small-RNAs in a large sample size of humans and it is the
largest data set of exRNAs from human samples. Previous studies
of plasma RNAs have focused on the detection of miRNAs,
essential exRNAs that regulate the expression of messenger
RNAs19,20. Their abundance and ubiquity and their known
Table 1 | exRNA factor structured in Framingham Heart Study cohort (N¼ 2,763).
Rate expressed Cq Targets* Unique targets*
N Mean±s.d. (range) Mean±s.d. (range) (N) (N)
miRNA
F1 108 49.4±22.3 (11.9, 93.5) 19.2±1.5 (9.7, 20.9) 23,240 3,205
F2 67 4.4±2.0 (1.1, 8.4) 20.3±0.6 (16.8, 20.9) 18,898 2,718
F3 40 94.8±2.9 (84.2, 98.3) 17.9±1.6 (11.9, 19.9) 15,487 645
F4 17 68.6±21.9 (22.7, 94.3) 19.9±0.6 (18.8, 20.9) 13,928 156
None 100 34.2±24.0 (1.4, 95.3) 20.4±0.6 (17.3, 21,2)
piRNA
F1 17 53.2±22.4 (11.5, 90.8) 20.0±0.5 (19.1, 20.9)
F2 14 0.3±0.1 (0.1, 0.5) 18.0±2.4 (13.3, 20.6)
F3 12 4.0±3.0 (1.4, 11.1) 20.6±3.2 (20.1, 21.1)
F4 7 51.9±20.1 (22.1, 77.3) 20.3±0.4 (19.6, 20.7)
None 47 18.9±29.2 (0.4, 99.6) 20.4±1.3 (16.0, 21.3)
snoRNA
F1 13 4.6±2.0 (2.0, 8.3) 20.0±0.5 (19.0, 20.7)
F2 9 29.3±18.4 (13.3, 65.9) 20.3±0.7 (18.6, 20.8)
F3 8 67.8±22.9 (43.6, 95.0) 19.6±0.9 (18.3, 20.4)
F4 6 17.3±9.0 (8.8, 30.6) 20.4±0.1 (20.2, 20.6)
None 7 41.1±32.2 (9.6, 92.7) 20.3±0.7 (19.4, 20.9)
*miRDB Version 5.0 target predictions available at (http://mirdb.org/miRDB/download.html).
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bidirectional transport between cells and plasma is important as
they are evolutionarily widespread, and participate in a wide
range of genetic regulatory pathways1. By regulating cell fate
choices and transitions between pluripotency and differentiation,
miRNAs help to orchestrate developmental events and play a role
in tissue homoeostasis that may be important for disease21–23.
Previous studies have shown that cellular circulating transcripts
are associated with CVD and its risk factors4,5,15,24–28 and future
studies utilizing this data set can begin to explore the role of
piRNAs and snoRNAs in health and disease. Although the source
of circulating exRNA remains unclear, and concerns about
cellular contamination vs exosomal release remain, the cellular
secretion of unique miRNAs, piRNAs and snoRNAs suggests
process speciﬁcity29–32. While a strength of our study is that the
large numbers allow greater conﬁdence if potential sample
preparation contamination occurred, this study, as with all
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Figure 6 | MicroRNA target prediction and pathway enrichment analysis. (a) Venn diagram showing the overlaps of the predicted sets of unique
mRNAs targeted by miRNAs for each factor. (b) Signiﬁcantly (Benjamini Hochberg corrected P valueo0.05) enriched KEGG pathways for target genes
for factors 1–4. The number of miRNA involved in targeting at least one gene in a given pathway are shown in parentheses.
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plasma exRNA studies, cannot deﬁnitely conclude that all
measured circulating exRNAs are due to release in vivo.
Consistent with a previous study of miRNAs33, we found many
associations with age and extended these ﬁndings to include
snoRNAs and piRNAs. In addition, using a large population
allowed for factor analyses demonstrating enrichment of speciﬁc
pathways, however, it also highlights the complexity of using
these data for target prediction.
While our ﬁndings are consistent with previous studies
demonstrating the presence of numerous miRNAs in plasma,
this is the ﬁrst study to report widespread presence of
non-miRNA small-RNAs in plasma. The ability to broadly detect
non-miRNAs was partially due to the National Institute of Health
(NIH) Common Fund strategic planning process established a
new program to study extracellular RNAs (exRNAs). One goal of
this program was to develop a catalog of exRNAs in human body
ﬂuids to facilitate investigation of their roles in health and disease.
A crucial objective of this program was to develop bioinformatic
tools and pipelines to assist in the broad identiﬁcation of exRNAs
from RNAseq. As part of the Extracellular RNA Communication
Consortium, using these recently developed tools, we were able to
broadly identify a wide range of extracellular small non-protein-
coding RNAs using human plasma. Despite ﬁnding numerous
piRNAs and snoRNAs in the circulation, their signiﬁcance to
biological processes or disease is unknown. The observation that
nonhuman exRNAs are widely, albeit sporadically, present in
human plasma is novel and noteworthy as is the striking
consistency between separate human studies from diverse
populations and utilizing different methods of RNA isolation
and RNAseq. Fuller analyses in regards to exact levels of
expression would need to be conducted in another large
comparable cohort.
Recently, functional roles for piRNA beyond transposon
silencing have emerged including regulation of mRNA. piRNAs
are a class of small-RNAs that are likely to have existed since the
origin of metazoans. Piwi-associated RNAs, as compared with
miRNAs, are a distinct class of 26–31 nucleotide-long RNAs
produced by a Dicer-independent mechanism. They are asso-
ciated with Piwi-class Argonaute proteins. Studies in ﬂies, mice
and other species implicate these piRNAs in the regulation of
germ line development, the silencing of selﬁsh DNA elements,
and maintaining germ line DNA integrity. While piRNAs map to
unique sites in the human genome, the role of piRNAs in human
plasma remains to be elucidated although the association of
several with age is intriguing. Also fascinating is the observation
of homology between the FHS and validation cohorts (15%), as
piRNAs are the largest class of small noncoding RNA molecules
expressed in animal cells and it is thought that there are many
hundreds of thousands distinct piRNA species. Small-RNA
sequencing has been performed in extensive mouse and rhesus
macaque samples and showed the presence of piRNA, displaying
all known characteristics of piRNA in multiple somatic tissues,
suggesting that they may play a role outside of the germ line34.
They have also been identiﬁed in limited bovine samples from
whole blood and plasma35.
We also found 74 snoRNAs in plasma and there is a paucity of
information in regards to their expression in human tissue.
Although they have been previously reported by RNAseq14, their
role in the circulation is currently not clear. Limited numbers of
snoRNAs have been shown in lung tissue and plasma from
patients with non-small cell lung cancer36 and in a small cohort
of patients with multiple myeloma37. The remarkable consistency
(over 50%) between the identiﬁable snoRNAs from the FHS
cohort with the conﬁrmation cohort is striking. However, further
studies will be required to determine the reason for this speciﬁc
pattern of expression.
There are limitations to this study including an older
population and a lack of ethnic diversity. However, future studies
as part of this consortium will process samples from several
ethnically and racially diverse groups as well as younger
populations. Our exRNA proﬁling was performed from plasma
samples and, as such, does not provide information about
exosomal vs protein-bound RNAs in the large population study.
The data suggest that there is a decrease in non-exosomal
fractions compared with exosomes but we do not know, based on
these experiments, which speciﬁc cells the exosomes or protein-
bound exRNAs are derived. As expected, the content in the
plasma is decreased as compared with the nucleated cells. In
addition, our identiﬁcation of piRNAs is limited in that these are
based on sequences that speciﬁcally map to piRNAs and we have
not established functionality. However, we performed several
experiments to establish that targets found as mapping to piRNAs
have 30modiﬁcations. Analyses of cDNAs made for miRNAs and
snoRNAs with piRNA assays by RT-qPCR, showed that our
cDNA reactions for piRNAs were also speciﬁc to the piRNA 30
methylation modiﬁcation. Additionally, we performed oxidation
experiments using plasma exRNAs and show piRNA, but not
miRNA, expression in both oxidized and nonoxidized samples.
Lastly, while some participants are missing speciﬁc abundant
miRNAs and/or piRNAs, we do not see uniformly missing
exRNAs in these few participants suggesting that it is related to
expression and not artifact.
In summary, a limited number of studies have demonstrated a
wide variety of exRNAs by RNAseq in humans, but the presence
Table 2 | exRNA expression in each cell type relative to
isolated plasma.
Not
signiﬁcant
vs plasma
Upregulated
in plasma
Downregulated
in plasma
(N) (N) (N)
piRNA (N¼ 97)
B cells 62 35
Exosomes 89 7 1
Neutrophils 67 30
Peripheral mononuclear
blood cells
49
Platelets 49 48
Red blood cells 48 49
T cells 57 40
snoRNA (N¼43)
B cells 2 41
Exosomes 36 6 1
Neutrophils 6 37
Peripheral mononuclear
blood cells
1 42
Platelets 22 21
Red blood cells 4 39
T cells 43
miRNA (N¼ 331)
B cells 165 3 163
Exosomes 258 73
Neutrophils 282 10 39
Peripheral mononuclear
blood cells
61 2 268
Platelets 66 3 262
Red blood cells 100 4 227
T cells 85 3 243
Noted are the number of exRNAs in each isolated cell type that were not statistically signiﬁcantly
different from plasma, that were statistically signiﬁcantly enriched in plasma, and those that were
statistically signiﬁcantly depleted in plasma.
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of non-miRNA small-RNAs has not been previously shown. This
expansive study demonstrates widespread, variable expression of
novel human small exRNAs. Whether they contribute to cellular
homoeostasis or are associated with disease pathobiology is not
yet known. With broad patterns of expression, it is likely that
these intriguing exRNAs are contributing, not in isolation, but in
combination to regulate gene expression and inﬂuence cellular
functions.
Methods
Study population. The FHS is a long-term, ongoing cardiovascular study based in
Massachusetts. The FHS offspring study is a community-based, prospective study
of general disease as well as CVD and its risk factors. The study began in 1948 with
5,209 adult subjects from Framingham, and is now on its third generation of
participants. Cohorts undergo an examination at the FHS once every B4–8 years
and have been densely phenotyped over multiple prior examinations with a
wide variety of noninvasive tests. Participants in the Offspring Study have been
examined every 4–8 years since the 1970s, for eight prior exams. The participants
have extensive antecedent clinical data available and informed consent is obtained
for each visit.
Blood sample collection and plasma separation. Blood samples were previously
collected at Framingham Heart Study (Framingham, MA, USA) on Offspring exam
8 (March 2005–Jan 2008). Venipuncture was performed on study participants in a
supine position after an overnight fast, using standard venipuncture techniques.
Blood was collected into blood collection tubes with a liquid buffered sodium
citrate additive (0.105M). Blood collection tubes were centrifuged at 2,500g for
22min at 4 C. Plasma was separated from the cells and frozen at  80 C within
90min of draw.
An aliquot of 170 ml of plasma samples was transferred to our laboratory in
March 2014 and stored at  80 C. Freezers were both generator and CO2
backed up.
RNA isolation from plasma. RNAs was isolated from plasma samples using a
miRCURY RNA Isolation Kit—Bioﬂuids (Cat. No: 300112, Exiqon, Denmark).
A total of 130 ml of plasma samples were used in each RNA isolation. The kit is
designed to isolate RNA from 200 ml of plasma. We replaced the remaining
volume with nuclease-free water. Manufactures protocol was followed with one
modiﬁcation that was reducing the elution volume from 50 ml nuclease-free water
to 30ml. After thawing the plasma samples tubes were mixed by inverting.
Then plasma samples were centrifuged at 8,000g for 5min. One-hundred thirty
microlitre of plasma samples from the top of the tubes transferred into a new 2.0ml
DNA LoBind tubes (Cat. No: 022431048, Eppendorf, Germany) and 70 ml nuclease-
Free water add to each sample to complete the volume to 200ml. Sixty microlitre
Lysis Solution BF were added to each sample. Tubes were vortexed for 15 s.
Tubes were incubated for 5min at room temperature. Twenty microlitre Protein
Precipitation Solution BF were added into each tube and tubes were vortexed for
15 s. Vortexed tubes were incubated for 1min at room temperature. Tubes were
centrifuged for 3min at 16,000g. Clear supernatants were transferred into a clean
2.0ml DNA LoBind tubes. Two-hundred seventy microlitres of Isopropanol was
added into each tubes and tubes were vortexed for 5 s. Tubes were centrifuged
brieﬂy (2–3 s) to collect all liquid at the bottom of the tubes. MicroRNA Mini Spin
Columns BFs connected to vacuum manifold called QIAvac 24 Plus (Cat. No:
19413, Qiagen, Germany) by using VacValves (Cat. No: 19408, Qiagen, Germany).
Samples were transferred into microRNA Mini Spin Columns BFs using transfer
pipettes. Samples were incubated for 2min at room temp on microRNA Mini Spin
Column BFs with open lids. Vacuum pump was turned on until all liquids were
passed. Seven hundred microlitre of Wash Solution 2 BF (80ml Absolute ethanol
was added to Wash Solution 2 BF bottle) was added on microRNA Mini Spin
Column BFs and vacuum pump was turned on until all liquids were passed.
Two-hundred ﬁfty microlitre of Wash Solution 2 BF was added on microRNA
Mini Spin Column BFs and vacuum pump was turned on until all liquids were
passed. Hundred microlitre Wash Solution 1 BF was added on microRNA Mini
Spin Column BFs and vacuum pump was turned on until all liquids were passed.
Seven hundred microlitre of Wash Solution 2 BF was added on microRNA Mini
Spin Column BFs and vacuum pump was turned on until all liquids were passed.
Two-hundred ﬁfty microlitre Wash Solution 2 BF was added on microRNA Mini
Spin Column BFs and vacuum pump was turned on until all liquids were passed.
MicroRNA Mini Spin Column BFs were transferred to collection tubes (2.0ml
without a lid). Tubes were centrifuged for 2min at 11,000g at room temperature to
dry the membranes completely. Centrifuged microRNA Mini Spin Column BFs
were transferred into 1.5ml DNA LoBind tubes (conical bottom tubes) and 30 ml of
nuclease-free water added directly onto membranes. Tubes were incubated for
1min at room temp with lids open. Lids were closed and centrifuged for 1min at
11,000g at room temperature. RNA samples were transferred into the V bottom,
snap cap, 0.5ml micronic tubes in two aliquots (12.5 ml in each) and capped. 2D
barcodes on the tubes were recorded and RNA samples were kept at  80 C. RNA
samples randomly analysed on Bioanalyzer 2100 by using RNA 6000 Pico Kit
(Agilent Technologies, Santa Clara, CA).
Standardization of sample volume. Throughout the experiments, we consistently
used 3 ml of vacuum concentrated RNA samples (isolated from 130 ml of plasma)
for all samples in library creations for small-RNAseq and 5 ml of RNA samples
(isolated from 130 ml of plasma) for all of the samples. A ﬁxed volume of plasma
from each participant in the RT-qPCR experiment workﬂow was used and the
same volume of RNA elution (30 ml) was used for all isolations keeping these
variables constant across all samples. Also, RNA volumes for reverse transcription
reactions (5ml) were constant for each sample. The same volume (3ml) of 1:5
diluted cDNA were used in each preampliﬁcation reaction. Two microlitre of 1:5
diluted preampliﬁed cDNA samples were used in each qPCR experiment. By doing
this we minimized the variance from sample to sample for possible variance for the
amount of RNA. Another reason we used a ﬁxed volume based approach is the
lack of consensus in regards to housekeeping small-RNAs for extracellular
compartments such as plasma.
Library preparation for RNA sequencing. Ion Total RNAseq Kit v2 (Cat. No:
4479789, Life Technologies, USA) was used for creating libraries for sequencing.
Manufacturer instructions were followed with a few exceptions as described
below. In collaboration with Life Technologies R&D team, we employed their
under-development Ion Adapter Mix to improve performance when using low
template amounts. A modiﬁed bead puriﬁcation method was also provided by
the Life Technologies R&D team.
Hybridization. On ice, the hybridization master mix was prepared by mixing 2 ml
of the Ion Adaptor Mix v2 with 3 ml of Hybridization Solution. Volumes of the
reagents for the master mix were adjusted according to the number of RNA
samples used. Five microlitre of the master mix was added onto 3 ml of isolated
small-RNA sample and the 8 ml mixture was pipetted up and down ﬁve times to
mix, then brieﬂy centrifuged to collect the liquid at the bottom of the tube. The
hybridization reaction was performed in a thermal cycler as follows: 65 C for
10min; and 16 C for 5min.
Ligation. Following hybridization, the ligation master mix was prepared on ice by
combining 10ml of 2X Ligation Buffer with 2 ml of Ligation Enzyme Mix. Volumes
of the reagents for the master mix were adjusted according to the number of
samples used. Twelve microlitre of ligation master mix was added to each 8 ml
hybridization mixture, for a total of 20 ml per reaction. The mixture was pipette up
and down 10 times to mix, then centrifuged brieﬂy to collect the liquid at the
bottom of the tube. The ligation reaction was performed in a thermal cycler at
16 C for 16 h.
Reverse transcription. After ligation, the RT master mix was prepared on ice by
combining 2 ml of nuclease-free water, 4 ml of 10 RT Buffer, 2 ml of 2.5mM dNTP
Mix and 8 ml Ion RT Primer v2 for a total volume of 16 ml. Volumes of the reagents
for the master mix were adjusted according to the number of samples used. 16 ml of
RT master mix and 20 ml of ligation reaction mixture were mixed, pipette up and
down and incubated in a thermal cycler with a heated lid at 70 C for 10min, then
snap-cooled on ice. Four microlitre of 10 SuperScript III Enzyme Mix were
added to each ligated RNA sample and gently mixed, after which the mixture
was incubated in a thermal cycler with a heated lid at 42 C for 30min.
First bead puriﬁcation. The cDNA was them puriﬁed using MagMAX beads.
Before the addition of the cDNA samples, 5 ml of the beads were put into one well
of a 96-well plate for each sample. Then, 250 ml of Binding Solution Concentrate
was added to each well containing beads, and the mixture was pipetted up and
down 10 times. Sixty microlitre of nuclease-free water were added to each of the
40 ml RT reactions and transferred to one of the wells of the 96-well plate. 275 ml of
100% ethanol were added to each well and mixed by pipetting up and down. Then
the plate was placed on the magnetic stand for 5min, after which the supernatant
was removed carefully without disturbing the beads. 150 ml of Wash Solution
Concentrate was added onto the beads and incubated for 30 s. While the plate was
still on the magnetic stand the Wash Solution Concentrate was removed. Any
leftover Wash Solution Concentrate was removed by using a 10 ml pipette. The
beads were then air-dried for 2min and then the plate was removed from the
magnetic stand. 12ml of pre-warmed (37 C) nuclease-free water was added on
beads, mixed by pipetting up and down 10 times and incubated off the magnetic
stand for 1min. The plate was then put back onto the magnetic stand for 1min.
Puriﬁed cDNA was removed carefully and transferred into a DNA LoBind
0.5ml tube.
Ampliﬁcation of cDNA. Following the bead puriﬁcation, the PCR master mix was
prepared by combining 45 ml of Platinum PCR SuperMix High Fidelity and 1 ml of
Ion Xpress RNA 30 Barcode Primer for a total volume of 46 ml per sample. Volumes
of the reagents for the master mix were adjusted according to the number of
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samples used. One microlitre of a selected Ion Xpress RNAseq Barcode primer was
individually added into each sample tube, after which 6 ml of cDNA samples were
added into each tube. Tubes were mixed and thermal cycling performed on ProFlex
3 32 block Thermal Cycler (Life Technologies, USA) as follows: one cycle holds
at 94 C for 2min, followed by two cycles of 94 C for 30 s, 50 C for 30 s and 68 C
for 30 s, followed by 18 cycles of 94 C for 30 s, 62 C for 30 s and 68 C for 30 s,
followed by a one cycle holding at 68 C for 5min.
Second bead puriﬁcation. The ampliﬁed cDNA samples were puriﬁed by using
MagMAX beads. Five microlitre of the beads were added to one well of a 96-well
plate for each sample. A total of 280ml of binding solution concentrate were added
to each well containing beads, and mixed by pipetting up and down 10 times.
Twenty-seven microlitre of nuclease-free water were added to each of the 53 ml
ampliﬁed cDNA reactions and transferred to one of the wells of the 96-well plate.
Two-hundred thirty microlitre of 100% ethanol were added to each well and mixed
by pipetting up and down. The plate was then placed on the magnetic stand for
5min, after which the supernatant was removed carefully without disturbing the
beads. One-hundred ﬁfty microlitre of wash solution concentrate were added and
incubated for 30 s. While still on the magnetic stand, the wash solution concentrate
was removed. Any leftover wash solution concentrate was removed by using 10 ml
pipette. The beads were air-dried for 2min and the plate was removed from the
magnetic stand. Ten microlitre of pre-warmed (37 C) nuclease-free water were
added onto the beads, mixed by pipetting up and down 10 times and incubated off
the magnetic stand for 1min. The plate was then moved back on the magnetic
stand for 1min. Then, the supernatant containing Puriﬁed Ampliﬁed cDNA was
removed carefully and transferred into a DNA LoBind 0.5ml tube. Ampliﬁed
cDNA samples were analysed on Bioanalyzer 2100 by using High sensitivity
DNA Chip (Agilent Technologies, Santa Clara, CA) to quantify the concentration
of PCR bands.
Template preparation for RNA sequencing. The Ion Chef System and Ion PI IC
200 kits were used for template preparation. The entire procedure was automated
by the Ion Chef System. At the end of the template preparation, loaded PI Chips
(Life Technologies, USA) were ready for sequencing.
RNA sequencing on ion proton system. Sequencing reactions were performed on
the Ion PI Chip Kit v2 BC and Ion Proton System (Life Technologies, USA) by
using the Ion PI Sequencing 200 Kit v2 (Life Technologies, USA). Sequencing reads
were at maximum 200 nucleotides.
RNAseq from plasma. The cohort based at the Beth Israel Deaconess Hospital,
consisted of normal subjects (n¼ 3; 33% female, age 25.7±9 years) and post-MI
patients who had plasma collected within 4 weeks after presentation (n¼ 40,
20% female, BMI 28.9±5.2 kgm 2). Patients studied after MI were derived
from a completed, multi-centre study of post-MI cardiac structural changes
(PROSPECT-CMR study; ClinicalTrials.gov identiﬁer: NCT00729430). Patients
in this study were enrolled 14–28 days after an acute MI, with subsequent
randomization to ﬁsh-oil therapy and follow-up at 6 months after randomization.
A subset of plasma samples from the baseline (before randomization) study visit
was used in RNA sequencing for this analysis.
RNA isolation from plasma. Total RNA was extracted from 1ml of plasma using
the miRCURY RNA extraction kit for Bioﬂuids (Exiqon) with a modiﬁed lysis step.
Samples were lysed at 50 C for 20min with GITC-containing lysis buffer
(provided in the kit) and 10mgml 1 proteinase K in a 0.5% SDS solution
(to a ﬁnal SDS concentration of 0.005%). Following lysis, RNA extraction was
performed according to manufacturer’s protocol. Resultant RNA was treated with
T4 polynucleotide kinase (NEB) and quantiﬁed using Quant-iT RiboGreen RNA
Assay (Life Technologies) according to manufacturers’ protocols.
Library preparation for RNA sequencing. Small-RNA libraries were constructed
using the NEBNext Multiplex Small-RNA Library Prep Set for Illumina (Set 1),
with adaptors diluted 1:6 with nuclease-free water to reduce adaptor dimer
formation and sequenced on the Illumina HT HiSeq platform.
Sequencing data analysis using Genboree-sequencing pipeline. Small-RNAseq
reads were processed and quantiﬁed using the exceRpt tool available on the
Genboree Workbench [http://www.genboree.org/]. ExceRpt incorporates several
modiﬁcations to existing analysis methods used to assess cytosolic microRNAs
(miRNAs) that speciﬁcally address experimental issues pertinent to exRNA
proﬁling, such as variable contamination of ribosomal RNAs, the presence of
endogenous non-miRNA small-RNAs, and the presence of exogenous small-RNA
molecules derived from a variety of plant, bacteria, and viral species. Brieﬂy, the
software processes each sample independently through a casade of read-alignment
steps designed to remove likely contaminants and endogenous sequences before
aligning to exogenous miRNAs:
(1) 3’ adapter clipping. The adapter clipping is required due to the fact that the
majority of small-RNAs are shorter in length than the number of nucleotides
sequenced. The adapter removal is performed using the FastX software (v.0.0.13;
http://hannonlab.cshl.edu/fastx_toolkit/) using the fastx_clipper tool, and the
clipping requires identiﬁcation of at least 7 adapter bases at the 30 end of a read and
that clipped reads must be longer than 15 nt.
(2) Explicit quality control and ﬁltering is performed on the sequencing reads
from each sample by removing likely contaminant sequences derived from
laboratory or rRNA contamination. First, rReads are aligned, using Bowtie2
(ref. 38), to UniVec, a library of common contaminant sequences maintained by
the NCBI, and reads with valid alignments counted, archived and removed from
further consideration. Second, reads are aligned, again using Bowtie2, to the
human ribosomal RNA (rRNA) precursor sequences (the full 45S, and 5S, and
mitochondrial rRNA sequences) as these rRNAs typically constitute the source
of most of the confounding contamination in any small-RNAseq experiment,
especially those from extracellular preparations. Reads aligned to the rRNAs are
counted, archived, and removed from further consideration in subsequent
alignment steps. Bowtie2 is used in both of these steps due to its superior alignment
speed, tolerance for gapped alignments, and tolerance for low-quality read
sequences.
(3) At its core, exceRpt utilizes the sRNAbench software tool, which is itself
based on the miRanalyzer tool39,40 for mapping and proﬁling small-RNA libraries.
On input to sRNAbench, for each sample, identical clipped-read sequences are
counted and collapsed to a single entry and reads containing N’s are removed.
Clipped, collapsed reads are mapped directly to the human genome and pre-
miRNA sequences using Bowtie1 (ref. 38), allowing for only a single mismatched
base in each alignment. Bowtie1 is used for this in conjunction with a 19 nt seed in
order to allow local alignments at the 50-end of a small-RNA that might exhibit 30
non-template additions. The miRNA library used for alignment is obtained from
miRBase (v21) (ref. 41). The output from this read-alignment, for each sample, is a
collection of ﬁles containing the alignment outcomes (pre-miRNA and mature-
miRNA IDs) for each read, the read-stack covering each pre-miRNA sequence, and
the mapping of the pre- and mature-miRNA sequences with respect to the human
genome. These alignments are parsed and used in conjunction with a pre-miRNA
secondary-structure prediction, via RNA-fold provided in the Vienna software
suite42,43 to enable veriﬁcation through stability analysis of the various pre-miRNA
hairpin sequences.
(4) Following alignment to the provided miRNA library, reads that did not align
in any of the previous steps are mapped against a variety of small-RNA libraries
including (with no signiﬁcance to the ordering): tRNAs from gtRNAdb43, piRNAs
from RNAdb44,45, snoRNAs from snoRNA-LBME-db45 and snRNAs and other
RNA sequences from RFam46. In both steps 3 and 4 reads were allowed to
multi-map to different annotated transcripts and in cases where this occurred, the
read was split proportionally based on the number of equally valid alignments.
(5) Those reads that are not mapped in any of the above steps are taken forward
to the ﬁnal stage of the pipeline where they are aligned, again using sRNAbench, to
the complete set of annotated plant and virus pre-miRNA sequences in miRBase.
RNAseq from the FHS offspring 8 participants. Using the small extracellular
RNAseq pipeline (exceRpt) described above, each of the 40 small-RNAseq samples
from different individuals were processed independently. The output of the
pipeline is the expression values in terms of read counts for all annotated human
miRNAs, piRNAs, snoRNAs and tRNAs from miRBase v21 for each sample. The
expression value for each sample was normalized to units of RPM total mapped
reads. Small-RNAs that had an average expression across the 40 samples above
RPM 41 K were selected for RT-qPCR analysis across the entire cohort. This
results in a total of 1,192 small-RNAs that included 669 human miRNAs,
144 human piRNAs, 74 human snoRNAs and 305 tRNAs. For the conﬁrmation
cohorts, differential expression between groups was performed with the
sRNAbenchDE tool using RPM normalized by the total number of reads mapped
to the genome for the primary alignment of each sRNA species. Differential
expression fold-change and P values were calculated with the edgeR47 package.
Reverse transcription for human small-RNAs. Speciﬁc piRNAs, snoRNAs and
miRNAs were chosen directly from the list generated by RNAseq. The most
abundant and most commonly expressed exRNAs were selected for measurement
by RT-qPCR. RNA samples (2,763) were reverse transcribed by using miScript II
RT Kit (Cat. No: 218161, Qiagen, Fredrick, MD, USA) for measuring human
miRNAs and snoRNAs. For piRNAs, miScript Plant RT Kit (Cat. No: 218762,
Qiagen, Fredrick, MD, USA) was used due to piRNAs’ 30 modiﬁcations. Since plant
miRNAs have the same modiﬁcation this kit allowed us to study human piRNAs by
RT-qPCR. Manufacturer instructions were followed for both kits.
Reverse transcription of miRNAs and snoRNAs. For the reverse transcription
for miRNAs and snoRNAs the RNA samples were thawed on ice. Reverse
transcription master mix was prepared by combining 950 ml of 5 miScript
HiSpec Buffer, 475 ml of 10 miScript Nucleics Mix, 475 ml of nuclease-free water,
and 475 ml of miScript Reverse Transcriptase Mix for a total volume of 2,375 ml,
which was enough for four sets of 96 samples. Five microlitre of this mastermix
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were dispensed into each well of a 96-well PCR plate (Cat. No: AB17500, Bioplastic,
Netherland). Five microlitre of RNA samples were then transferred into each well
by using Vioﬂo384 Pipetting System (Integra Biosciences, Hudson, NH, USA) with
96-well head. Plates were sealed with EU optical Wide 8-Cap Strip Mats (Cat. No:
B57651, Bioplastic, Netherland), vortexed on a plate shaker for 10 s by pressing
with hands and then centrifuged for 1min at 500g in a small-plate centrifuge. The
samples were then incubated at 37 C for 60min and then at 95 C for 5min in the
ProFlex 96 block Thermal Cycler (Life Technologies, USA). When the reverse
transcription reactions were completed, plates were centrifuged for 1min, the strip
mats covering was removed and 40 ml of nuclease-free water were added into each
well by using Vioﬂo384 Pipetting System (Integra Biosciences, Hudson, NH, USA)
with 96-well head. Plates were again sealed with EU optical Wide 8-Cap Strip Mats
(Cat. No: B57651, Bioplastic, Netherland), vortexed on a plate shaker for 10 s by
pressing with hands and then centrifuged for 1min at 500g in a small-plate
centrifuge.
Ligation of piRNAs. RNA samples were thawed on ice. Ligation master mix was
prepared on ice by combining 950ml of 10 miScript Ligation Buffer, 950ml of
10 miScript Plant Adaptor and 475 ml of nuclease-free water for a total volume of
2,375 ml, which was enough for four sets of 96 samples. Five microlitre of this
mixture were dispensed into each well of a 96-well PCR plate (Cat. No: AB17500,
Bioplastic, Netherland). Then, 5 ml of RNA samples were transferred into each well
by using Vioﬂo384 Pipetting System (Integra Biosciences, Hudson, NH, USA) with
96-well head. Finally, 10 ml of 2 miScript Ligation Activator were pipetted onto
each well very slowly, due to viscosity, by using Vioﬂo384 Pipetting System (Integra
Biosciences, Hudson, NH, USA) with 96-well head. The ﬁnal mixture was mixed
using Vioﬂo384 Pipetting System (Integra Biosciences, Hudson, NH, USA) with
96-well head by pipetting up and down 10 times. Plates were sealed with EU optical
Wide 8-Cap Strip Mats (Cat. No: B57651, Bioplastic, Netherland) and centrifuged
for 1min at 500g in a small-plate centrifuge. Samples were then incubated at 16 C
for 60min and at then 65 C for 20min in ProFlex 96 block Thermal Cycler
(Life Technologies, USA).
Reverse transcription of piRNAs. Reverse transcription master mix was
prepared on ice by combining 1,900 ml of 5 miScript Plant RT Buffer, 950ml of
10 miScript Plant RT Nucleics, 4,275ml of nuclease-free water and 475 ml of
miScript Plant Reverse Transcriptase for a total volume of 7,600 ml, which was
enough for four sets of 96 samples. 16 ml of this master mix were dispensed
into each well of a 96-well PCR plate (Cat. No: AB17500, Bioplastic, Netherland).
4 ml of the Ligation products were transferred into each well by using Vioﬂo384
Pipetting System (Integra Biosciences, Hudson, NH, USA) with 96-well head.
The mixture was mixed using Vioﬂo384 Pipetting System (Integra Biosciences,
Hudson, NH, USA) with 96-well head by pipetting up and down ten times.
Plates were then sealed with EU optical Wide 8-Cap Strip Mats (Cat. No: B57651,
Bioplastic, Netherland) and centrifuged for 1min at 500g in a small-plate
centrifuge. Samples were then incubated at 37 C for 2 h and then at 95 C for
5min at ProFlex 96 block Thermal Cycler (Life Technologies, USA). When reverse
transcription reactions were completed the plates were centrifuged for 1min, the
strip mats covering was removed and 80 ml of nuclease-free water were added into
each well by using Vioﬂo384 Pipetting System (Integra Biosciences, Hudson,
NH, USA) with 96-well head. Finally, plates were again sealed with EU optical
Wide 8-Cap Strip Mats (Cat. No: B57651, Bioplastic, Netherland), vortexed on a
plate shaker for 10 s and then centrifuged for 1min at 500g in a small-plate
centrifuge.
Preampliﬁcation of cDNAs. miScript Microﬂuidics PreAMP Kit (Cat. No:
331455, Qiagen, Fredrick, MD, USA) was used for preampliﬁcation reactions.
Manufacturer instructions were followed with a modiﬁcation to reduce the
preampliﬁcation reaction ﬁnal volume from 25 ml to 15 ml. Preampliﬁcation master
mix was prepared on ice by combining 1,425 ml of 5 miScript PreAMP Buffer,
570ml of HotStarTaq DNA Polymerase, 1,425 ml of miScript PreAMP Primer Mix,
1,995 ml of nuclease-free water and 285 ml of miScript PreAMP Universal Primer
(10 mM) for a total volume of 5,700 ml, which was enough for 4 sets of 96 samples.
12ml of this master mix was dispensed into each well of a 96-well PCR plate
(Cat. No: AB17500, Bioplastic, Netherland). Three microlitre of diluted cDNA
samples were transferred into each well by using Vioﬂo384 Pipetting System
(Integra Biosciences, Hudson, NH, USA) with 96-well head. Plates were sealed with
EU optical Wide 8-Cap Strip Mats (Cat. No: B57651, Bioplastic, Netherland),
vortexed on a plate shaker for 10 s and then centrifuged for 1min at 500g in a
small-plate centrifuge. The samples were then cycled in a ProFlex 96 block Thermal
Cycler (Life Technologies, USA) as follows: one cycle of the PCR initial activation
step for 15min at 95 C, followed by two cycles of denaturation for 30 s at 94 C,
annealing for 60 s at 60 C and extension for 60 s at 60 C, followed by 10 cycles of
denaturation for 30 s at 94 C, and annealing/ extension for 3min at 60 C.
When preampliﬁcation reactions were completed the plates were centrifuged
for 1min, the strip mats covering was removed and 2 ml of SR1 (side reaction
reducer¼ Exonuclease I) was added into each well by using Vioﬂo384 Pipetting
System (Integra Biosciences, Hudson, NH, USA) with 96-well head. Plates were
then sealed again with EU optical Wide 8-Cap Strip Mats (Cat. No: B57651,
Bioplastic, Netherland), vortexed on a plate shaker for 10 s and then centrifuged for
1min at 500g on a small-plate centrifuge. Samples were then cycled in at ProFlex
96 block Thermal Cycler (Life Technologies, USA) as follows: 37 C for15 min; and
95 C for 5min. When SR1 reactions were completed, the plates were centrifuged
for 1min, the strip mats covering was removed and 58 ml of nuclease-free water was
added into each well by using Vioﬂo384 Pipetting System (Integra Biosciences,
Hudson, NH, USA) with 96-well head. Plates were then sealed again with EU
optical Wide 8-Cap Strip Mats (Cat. No: B57651, Bioplastic, Netherland), vortexed
on a plate shaker for 10 s and then centrifuged for 1min at 500g on a small-plate
centrifuge.
Real-time PCR miRNA proﬁling. Assay plates and preampliﬁcation primer mix
preparation was performed according to the miScript Microﬂuidics Handbook
(https://www.qiagen.com/us/resources/resourcedetail?id=34798505-6ff7-459c-
8896-2ee777093f6e&lang=en)). Human miRNA Assays were purchased from
Qiagen in dried down format. First, assay plates were centrifuged at 1,500g for
10min. Then, 27.5 ml of nuclease-free water was added into each well and incu-
bated at room temperature for 10min. Plates were vortexed in a plate shaker for
3min at room temperature. These assay were at 100 mM concentrations. Eighteen
microlitre of these assays were taken and combined in a reservoir (43 snoRNA
assays were added separately, see below) and 2,106 ml of nuclease-free water was
added to make a preampliﬁcation primer pool. 14.25 ml of nuclease-free water was
added onto the remaining 9.5 ml of 100 mM assays for a total volume of 23.75 ml and
ﬁnal concentration of 40 mM. Equal volume of miScript Microﬂuidics Universal
Primer (40 mM) was added onto these assays for a total volume of 47.5 ml and ﬁnal
assay concentration of 20 mM. Equal volume of the 2X Assay Loading Reagent
(Cat. No: 100-7611, Fluidigm, South San Francisco, CA, USA) (47.5 ml) was added
onto these assays. The assays were now ready to load into Dynamic Arrays. 28 ml
aliquots of these assays were aliquoted in 96-well Piko plates (Cat. No: SPL0960,
Fisher Scientiﬁc, USA), sealed and stored at  20 C. snoRNA assays and piRNA
assays were custom designed by Qiagen and synthesized primers were delivered
at 100 mM concentration in liquid form. These assays were also prepared as
described above.
Dynamic array preparations for qPCR. Control line ﬂuid was injected into
appropriate positions on two Dynamic Arrays 96.96 GE and the Dynamic Arrays
were placed into IFC Controller HX for priming. While priming was performed
(B20min), qPCR master mix was prepared on ice by combining 720ml of
Microﬂuidics qPCR Master Mix (Qiagen), 72 ml of 20 DNA Binding Dye Sample
Loading Reagent (Fluidigm, PN 85000746), and 168.00 ml of nuclease-free water for
a total of 960 ml, which was enough for two sets of 96 samples. Four microlitre of
this master mix were dispensed into each well of a 96-well PCR plate (Cat. No:
AB17500, Bioplastic, Netherland). Two microlitre of diluted preampliﬁed cDNA
samples were then transferred into each well using Vioﬂo384 Pipetting System
(Integra Biosciences, Hudson, NH, USA) with 96-well head. Plates were then sealed
with EU optical Wide 8-Cap Strip Mats (Cat. No: B57651, Bioplastic, Netherland),
vortexed on a plate shaker for 10 s and then centrifuged for 1min at 500g on a
small-plate centrifuge. Five microlitreof this mixture were aspirated by using Viaﬂo
8-channel electronic pipet and dispensed into sample inlets of Dynamic Arrays as
4.75 ml to avoid creating bubbles. 4.75 ml of assays were aspirated by using Viaﬂo
8-channel electronic pipet and dispensed into sample inlets of Dynamic Arrays as
4.50 ml to avoid creating bubbles. Dynamic Arrays were placed into the IFC
Controller HXs and the standard Load script was started (B90min). When the
loading script was ﬁnished, dynamic arrays were loaded into the BioMark reader
and cycling was performed as follows: thermal mix for 2min at 50 C; 30min at
70 C; and 10min at 25 C, followed by PCR initial activation step for 10min at
95 C, followed by a three-step cycling for 23 cycles of denaturation for 15 s at
94 C, annealing for 30 s. at 55 C and extension for 30 s. At 70 C, followed by
performing ﬂuorescence data and collection and dissociation curve analysis. ROX
was used as a passive reference dye. Linear derivative and user global setting
(Threshold setting 0.002) were used as setting parameters, samples and assays
names were entered and basic real-time PCR analysis was performed on BioMark
Real-Time PCR Analysis software. Quantiﬁcation cycle (Cq) values were exported
as csv ﬁles.
Poorly performing PCR assays. Poorly performing assays were removed from
analysis. Assays that had consistent, nonvariable expression in samples and
no-template RT Control samples were removed as this result demonstrates lack of
assay speciﬁcity for the target. Using these criteria, a total of 15 assays were
removed from the initially designed 486 assays.
Blood cell isolation. Red blood cells. Citrated whole blood was centrifuged at 150g
for 17min with no brake. After the platelet rich plasma is removed, 2ml RBCs were
removed and processed as previously described[1]48. Brieﬂy, RBC samples were
centrifuged 500g for 10min at 4 C. The top aqueous layer and white blood cells
were removed and 1ml RBCs from the bottom of the tube was diluted with 1ml of
RBC Wash Buffer (21.0mM TRIZMA, 4.7mM KCl, 2.0mM CaCl2, 140.5mM
NaCl, 1.2mM MgSO4, 5.5mM glucose and 0.5% BSA at pH 7.4). Samples were
centrifuged as before. The top aqueous layer was removed and the sample was
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diluted 1:1 with RBC Wash Buffer and centrifuged as before 2 more times. After
the ﬁnal centrifugation, the aqueous layer was removed and 100 ml RBCs were
removed from the bottom of the tube for RNA isolation and ﬂow cytometry
analysis.
Platelets—Citrated whole blood was centrifuged at 150g for 17min with no
brake. Fifty per cent of the resulting platelet rich plasma was diluted 1:1 with
platelet wash buffer (10mM sodium citrate, 150mM sodium chloride, 1mM
EDTA, 1% dextrose, pH 7.4, with 1:10,000 prostaglandin E1) and centrifuged at
300g for 4min with no brake. Seventy-ﬁve per cent of the resulting supernatant was
diluted again 1:1 with platelet wash buffer and centrifuged as before. Seventy-ﬁve
per cent of the resulting supernatant is run through a 5 mm syringe ﬁlter
(Millipore), followed by the same volume of platelet wash buffer. The platelets were
pelleted by centrifuging at 740g for 17min with low brake. The resulting pellet was
used for RNA isolation and ﬂow cytometry analysis.
Plasma. Citrated whole blood was centrifuged at 150g for 17min with no brake.
Two millilitres of platelet rich plasma was then centrifuged at 16,000g for 5min.
The supernatant was then serial centrifuged at 300g for 10min, 2,000g for 20min,
and 10,000g for 30min at 4 C to remove cellular debris. The resulting supernatant
was then used for RNA isolation and ﬂow cytometry analysis, while another
portion was used to isolate exosomes.
Exosomes. A portion of the plasma isolated above was used to isolate exosomes
using magnetic beads from the ExoCap for Serum Plasma Kit (JSR Life Sciences)
according to the manufacturer’s instructions for qRT-PCR. RNA was isolated from
these exosomes as well as analysed by ﬂow cytometry.
Peripheral blood mononuclear cells. Citrated whole blood in a CPT Vacutainer
tube (Becton Dickinson) was centrifuged at 1,800g for 35min. The resulting cell
layer was centrifuged at 288g for 17min. The pellet was washed in 1 PBS and
centrifuged at 2,000g for 10min two times. The ﬁnal pellet was resuspended in 1
PBS and run through a 5 mm ﬁlter, which is then washed and the eﬂux opening
cleared. The ﬁlter was reversed and ﬂushed with 1 PBS. This process was
repeated one more time and the resulting cell suspension was pelleted by
centrifugation at 2,000g for 10min. Cells were used for RNA isolation and ﬂow
cytometry analysis.
Neutrophils. Citrated whole blood collected in a CPT Vacutainer tube was
centrifuged at 1,800g for 35min. The resulting cell layer was treated with
ammonium chloride for 10min on ice to lyse RBCs. Neutrophils were then isolated
through negative selection using the Human Neutrophil Enrichment Kit (StemCell
Technologies) according to the manufacturer’s instructions. The resulting pellet
was used to isolated RNA and analysed by ﬂow cytometry.
T and B cells. Citrated whole blood collected in a CPT Vacutainer tube was
centrifuged at 1,800g for 35min. The resulting cell layer was washed and
centrifuged at 300g for 10min 2 times. Each cell type was isolated through negative
selection using the Pan B Cell Isolation Kit or Pan T Cell Isolation Kit (Miltenyi
Biotec) according to the manufacturer’s instructions. The resulting cell pellet was
used to isolate RNA and analyse through ﬂow cytometer.
Flow cytometry. The above mentioned samples were analysed by ﬂow cytometry
to determine purity using the ﬂowing ﬂuorescently conjugated antibodies and
corresponding isotype controls (eBioscience): anti-human CD235a FITC (RBC
marker), anti-human CD41a PerCp-eFluor 710 (platelet marker), anti-human
CD56 APC (NK cell marker), anti-human CD14 APC (monocyte marker),
anti-human CD15 FITC (granulocyte marker), anti-human CD16 PE-Cyanine7
(neutrophil marker), anti-human CD9 FITC (exosome marker), anti-human CD3
FITC (T cell marker) and anti-human CD19 PerCP-Cyanine5.5 (B cell marker).
Samples were analysed using a FACSCaliber ﬂow cytometer with Cell Quest
Software (BD Bioscience).
Blood cell isolation purity. Each blood component—plasma, exosomes, platelets,
PBMCs, RBCs, T Cells, B Cells and neutrophils—was isolated as described from six
healthy donors (three males and three females; mean age of 41.67; 100%
Caucasian). Flow cytometry was performed to verify the cell type isolated
and identify any major contaminants. For exosomes, the sample was positive
for CD9 (an exosome marker; Po0.001) and negative for platelets. For
platelets, the sample was positive for CD41 (a platelet marker; Po0.001) and
o5% positive for all other cell markers, except RBCs (11.1%±0.95). RBC
sample was positive for CD235a (a RBC marker; Po0.05) and o5% positive for
other cell markers. For PBMC sample, it was negative for RBCs but positive for
platelets (55.9%±0.87); potentially platelets attached to PBMCs, however, although
a large percentage, the relative abundance of platelet RNA (less than 1,000 fold),
makes this contamination unlikely to signiﬁcantly inﬂuence the gene expression
results.
Statistical methods for RNAseq. RNAseq data from the BIDMC validation
cohort was screened for all exRNAs with an average sequence read of at least 1,000
reads per million (RPM41 K) to compare with the RNAseq data generated from
the FHS. Any exRNA identiﬁed in the FHS cohort with average RPM41K
observed in the BIDMC cohort samples were considered overlapping. We report
the percentage of overlapping piRNA and snoRNA to indicate general validity
of the existence of these novel exRNA in plasma. To estimate the degree
co-expression across cohorts, we calculated the using Spearman’s rank correlation
of the log-transformed sequence number of reads for overlapping piRNA and
snoRNA.
Statistical methods for Framingham Heart Study cohort study. We studied
plasma samples for 2,822 eligible subjects from the FHS offspring 8 cohort.
Fifty-nine (2%) of subjects were excluded because of lab errors (that is, inaccurate
volume of plasma pipetted, n¼ 31; poor protein precipitation performance, n¼ 23;
or potential contamination, n¼ 5) resulting in 2,763 subjects for subsequent
analysis. All statistical analyses were performed using STATA 13.0. Descriptive
statistics are displayed as mean±s.d. for continuous variables and count
(percentage) for categorical variables. The qRT-PCR results (Cq) values were
normalized (DCq) by the global mean of expressed results to account for
inter-individual sample differences. exRNAs not expressed, that is, failing to
surpass the Cq within a set period, were ﬁrst assigned the maximum Cq value
(24 cycles) allowed according to our qRT-PCR procedures. Ordinary least-squares
linear regression models were used to test for association with median age and sex
and the normalized Cq value for each small-RNA assessed. To account for the
number of statistical comparisons conducted for each of the 471 exRNAs assessed
we employed FDR correction set at 5%.
We also estimated the association with the 10-year risk for CVD among
individuals 30–74 years of age using the FHS Risk score. This sex-speciﬁc
prediction score is generated from the following risk factors: age, diabetes,
smoking, treated and untreated blood pressure, total cholesterol and HDL levels.
Factor analysis. We conducted an exploratory principal factor analysis to identify
the factor structure of the miRNAs measured. Assigning non-expressed miRNAs
the maximum Cq of 24 in the normalization procedures could inﬂate the
correlation between unexpressed miRNAs. To account for the non-expressed
miRNA values (while maintaining some of the information contained the
abundance level) we scored the DCq values into an ordered three level variable:
0¼ no expression; 1¼ low expression (DCqZ0; that is, less expressed than global
mean); and 2¼ high expression (DCqo0; that is, more expressed than global
mean). From these ordered-DCq we generated the Spearman’s rank correlation
matrix for principal factor analysis. The number of retained factors was determined
by examination of the scree plot of the eigenvalues and considered varimax rotated
factor loadings 40.4 or o 0.4 deﬁning factor membership for each miRNA.
Statistical methods for blood cell isolation. Expression of each exRNA type was
compared in isolated blood cell components (N¼ 6 for each cell type). Ordinary
least-squares regression models were ﬁt to compare mean Cq values in each
cell component to plasma samples as the referent. DCq levels (that is, plasma-Cq—
blood cell component Cq values) at Po0.05 were considered statistically sig-
niﬁcant. The total number of piRNA (N¼ 97), snoRNA (N¼ 43) and miRNA
(N¼ 331) were stratiﬁed into those that were not statistically signiﬁcantly different
from plasma, those that were statistically signiﬁcantly upregulated in plasma, and
those that were statistically signiﬁcantly downregulated in plasma.
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